You can buy or sell Vical and other stocks, options, ETFs, and crypto commission-free!
Vical, Inc. engages in the research and development of biopharmaceutical products based on patented DNA delivery technologies for the prevention and treatment of serious and life-threatening diseases. It focuses on the antifungal VL-2397, which treats patients with invasive aspergillosis. Read More Its products include Vaxfectin, a cationic lipid formulation optimized to increase the immune response to vaccines. The company was founded by Howard E. Greene, Jr. Timothy J. Wollaeger, Karl Y. Hostetler, and Douglas D. Richman in April 1987 and is headquartered in San Diego, CA.
San Diego, California
52 Week High
52 Week Low
Research And Development
Seeking AlphaMar 7
Vical Is A Net Net In Liquidation Trading At Half Its Cash
On that date, book value per share was $2.24 and cash per share was $2.31 well above the current share price is $1.06. The company had cash and marketable securities of $50.5 million on December 31, 2018 and few liabilities. Going forward, R&D should be close to zero and administrative costs will be cut to less than $1.5 million per quarter. Net nets are hard to find. A net net is where the stock trades below working capital minus long-term liabilities. Usually they have all kinds of warts and are bleedi...
NASDAQ:VICL - Stock Price, News, & Analysis for Vical
Vical Incorporated engages in the research and development of biopharmaceutical products based on its DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases.
Guru FocusMar 1
Vical Inc (VICL) Files 10-K for the Fiscal Year Ended on December 31, 2018
Vical Inc (NASDAQ:VICL) files its latest 10-K with SEC for the fiscal year ended on December 31, 2018. Vical Inc is engaged in research and development of biopharmaceutical products based on its patented DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases.
Expected May 2, After Hours